Baht to 66.02 Million Baht or 13.95%, due to corporate marketing and sales alignment. 2. Our net loss for Q3 is 3.17 Million Baht compare to net loss 5.32 Million Baht Q on Q, due to decreasing in
noteworthy endeavor was the production of a short film featuring Prof. Dr. Krisana Kraisintu’s trip to Congo to disseminate knowledge on formulating an HIV “cocktail” drug, which was broadcast via online media
system of new medicines according to the additional standards SET forth by the Food and Drug administration. Therefore, it is necessary to use the capital to proceed the project amount 32,000,000 baht
Constructions (2) Registration of 100 drugs formulas (54 formulas for human medicine and 46 formulas for animals) owned by the seller (3) Registration of special drug formulas, consisting of 12 formulas including
and Drug Administration (CFDA), which took around 2 months, that we have got CFDA in early 2018. Sales by product category Consolidated financial statements For the three months period ended March 31
service Cost was 564.4 MB, an increase by 62.7 MB or 12.5% y-o-y is in alignment with the growth sale trend. The Company can control the cost of materials and labor costs in effectively, which results in an
alignment with the growth sale trend. The Company can control the cost of materials and labor costs in effectively, which results in an increase in gross profit compared to the same period last year and
growth shrimp frozen’ s purchase order. Cost Cost of sales and service Cost was 140.5 MB, an decrease by 0.05 MB or 0.04% y-o-y is in alignment with the growth sale trend. The Company can control the cost
additional income from contract manufacturing. Cost Cost of sales and service Cost was 279.4 MB, an increase by 5.7 MB or 2.1% y-o-y is in alignment with the growth sale trend. The Company can control the cost
the Company has additional income from contract manufacturing. Cost Cost of sales and service Cost was 415.9 MB, increased by 5.1 MB or 1.2% y-o-y is in alignment with the growth sale trend. The Company